In a groundbreaking development, Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a visionary player in the field of cancer immunotherapy, has just achieved a significant milestone. The company proudly announced the issuance of a pioneering patent that serves as the bedrock for BDC-3042, its groundbreaking clinical candidate.
This game-changing patent, officially designated as U.S. Patent 11,753,474 and titled “Anti-Dectin-2 Antibodies,” was granted by the U.S. Patent and Trademark Office (USPTO) on September 12, 2023. This achievement marks a pivotal moment in safeguarding the composition of matter and the innovative treatment methodologies associated with BDC-3042.
Explaining the significance of this milestone, Dr. Justin A. Kenkel, Co-inventor of BDC-3042 and Principal Scientist at Bolt Biotherapeutics, stated, “The issuance of this patent is an important milestone in protecting the composition of matter and methods of treatment for our BDC-3042 clinical candidate. This patent covers antibodies with a novel mechanism of action that leverages Dectin-2 agonism to repolarize tumor-associated macrophages into immunostimulatory, anti-tumor macrophages. We are on track to enter the clinic with BDC-3042 this year and are excited by the potential for this new approach to treat many different types of cancer.”
Notably, the patent’s claims are expected to remain valid until May 2041, barring any patent term adjustments or extensions that may further enhance its protective scope.
Bolt Biotherapeutics’ revolutionary myeloid-modulating antibody, BDC-3042, is on a mission to harness the incredible potential of myeloid cells, supercharging their anti-tumor capabilities. BDC-3042 is a remarkable agonist antibody with its sights set on Dectin-2, a potent immune-boosting pattern recognition receptor proudly displayed by tumor-associated macrophages (TAMs) dwelling within the tumor microenvironment.
These TAMs, often found in the heart of the tumor’s lair, have long played a pivotal role in crafting an immune-suppressed environment that allows tumors to thrive and flourish. However, here’s where BDC-3042 steps in and changes the game. By activating Dectin-2, it triggers a cascade of events within these TAMs, causing them to undergo a spectacular transformation into immunostimulatory “M1” macrophages.
But that’s not all; BDC-3042’s influence extends even further. It kickstarts the production of a diverse array of pro-inflammatory cytokines and chemokines, setting off a domino effect that awakens the immune system. Furthermore, this superhero antibody doesn’t stop there—it also encourages the expression of critical antigen presentation machinery. This, in turn, paves the way for the expansion of tumor-reactive T cells, sparking a formidable anti-tumor immune response.
In essence, BDC-3042 is a catalyst for unleashing the full potential of the body’s immune system, turning the tide against cancer in a way that’s as fascinating as it is promising.
About Bolt Biotherapeutics, Inc.
At Bolt Biotherapeutics, we’re not just another clinical-stage biopharmaceutical company—we’re pioneers on a mission to rewrite the story of cancer treatment. Our journey is guided by an unparalleled understanding of myeloid biology and a relentless commitment to reshaping the landscape of cancer therapeutics.
Our impressive pipeline reads like a roster of superheroes in the fight against cancer. Leading the charge is BDC-1001, a formidable HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) that’s already carving its path through Phase 2 clinical development. Backed by the success of a Phase 1 dose-escalation trial, BDC-1001 has not only proven its tolerability but also showcased early clinical efficacy that holds immense promise.
Joining the ranks is BDC-3042, our myeloid-modulating antibody with the potential to revolutionize cancer treatment. This trailblazing antibody, set to enter Phase 1 trials in the latter half of 2023, has already demonstrated its remarkable ability to transform tumor-supportive macrophages into tumor-destroying champions.
But that’s not all; we’re not fighting this battle alone. In strategic collaborations with top-tier biopharmaceutical companies, we’re developing a legion of Boltbody™ ISACs, each with its own unique powers and potential to redefine cancer therapy.
At Bolt Biotherapeutics, we’re not just developing drugs; we’re crafting a new era of hope and possibility for cancer patients worldwide.
Within the depths of this announcement lies a glimpse into our ambitious journey, one fraught with challenges and illuminated by possibilities. As we share our vision and progress, it’s crucial to acknowledge the inherent uncertainties that accompany our mission to reshape the landscape of our industry.
Embedded in these pages are not just words but a declaration of our unwavering commitment to push the boundaries of what’s possible. These forward-looking statements encapsulate our belief in the potential of our endeavors, our clinical trials, and the transformative impact we aspire to make.
Yet, as we venture into the unknown, we must acknowledge the shadows of uncertainty that dance alongside our every step. Risks, both known and unknown, stand as formidable adversaries, capable of altering our course and challenging our assumptions.
But in the face of uncertainty, we stand resolute, knowing that our journey is one that demands resilience and tenacity. We recognize that our current beliefs are merely snapshots in time, subject to the ebb and flow of information, innovation, and unforeseen events.
As we continue to forge ahead, we do so with an unwavering commitment to transparency, integrity, and the pursuit of knowledge. Our journey is a dynamic one, marked by the evolution of our beliefs, the adaptation of our strategies, and the relentless pursuit of our vision.
While we cannot predict the future, we can assure you that every step we take is grounded in the pursuit of excellence and the unwavering belief that we can make a difference. We invite you to join us on this remarkable journey, where the only certainty is our shared commitment to progress and innovation.